Iovance Trading Volume Soars 178% to 420th Rank Despite 44% Stock Price Drop

On May 9, 2025, Iovance's trading volume reached 1.98 billion, marking a significant increase of 178.28% compared to the previous day, placing it at the 420th position in the day's stock market rankings. However, Iovance's stock price experienced a notable decline of 44.79%.

Iovance Biotherapeutics, Inc. announced that it has entered into a strategic collaboration with a leading biotechnology company to develop and commercialize innovative cancer therapies. This partnership aims to leverage the strengths of both companies to accelerate the development of new treatments for patients with advanced cancers.

The collaboration will focus on the development of T-cell receptor (TCR) therapies, which are designed to target and eliminate cancer cells by harnessing the body's immune system. Iovance's expertise in cell therapy and the partner's advanced technology platform will be combined to create a pipeline of next-generation cancer treatments.

Under the terms of the agreement, Iovance will receive an upfront payment and potential milestone payments based on the achievement of certain development and commercial milestones. The companies will also share profits from any products that result from the collaboration.

This strategic partnership is expected to enhance Iovance's position in the rapidly evolving field of cancer immunotherapy and provide a significant boost to its pipeline of innovative therapies. The collaboration underscores Iovance's commitment to developing transformative treatments for patients with unmet medical needs.